Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. - Wikidata - awgldk - TriplyDB

Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production.

Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production.

http://www.wikidata.org/entity/Q30498613

about

Akt and mTOR in B Cell Activation and Differentiation mTOR Regulation of Lymphoid Cells in Immunity to Pathogens Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances Aging signaling pathways and circadian clock-dependent metabolic derangements Differential effects of rapamycin and dexamethasone in mouse models of established allergic asthma Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus.Rapamycin extends murine lifespan but has limited effects on aging.Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy.Involvement of mTOR in CXCL12 mediated T cell signaling and migration.Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia.Longevity, aging and rapamycin.A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses The AGC kinase SGK1 regulates TH1 and TH2 differentiation downstream of the mTORC2 complex.Rapamycin enhances adenovirus-mediated cancer imaging and therapy in pre-immunized murine hosts Peripheral residence of naïve CD4 T cells induces MHC class II-dependent alterations in phenotype and function.Dietary restriction and fasting arrest B and T cell development and increase mature B and T cell numbers in bone marrow.TOR in the immune system.mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells.Defining the role of TORC1/2 in multiple myeloma.TSC1 Promotes B Cell Maturation but Is Dispensable for Germinal Center Formation Essential role for retinoic acid in the promotion of CD4(+) T cell effector responses via retinoic acid receptor alpha The role of retinoic acid in tolerance and immunity.Attenuation of AMPK signaling by ROQUIN promotes T follicular helper cell formation.mTOR, linking metabolism and immunity Interaction of PDK1 with phosphoinositides is essential for neuronal differentiation but dispensable for neuronal survival Conditional Disruption of Raptor Reveals an Essential Role for mTORC1 in B Cell Development, Survival, and Metabolism.Phenotypic and Functional Comparison of Class Switch Recombination Deficiencies with a Subgroup of Common Variable Immunodeficiencies.Increased mammalian target of rapamycin complex 2 signaling promotes age-related decline in CD4 T cell signaling and function Rasgrp1 mutation increases naive T-cell CD44 expression and drives mTOR-dependent accumulation of Helios⁺ T cells and autoantibodies.B cell-specific deficiencies in mTOR limit humoral immune responses.IL-12hi rapamycin-conditioned dendritic cells mediate IFN-γ-dependent apoptosis of alloreactive CD4+ T cells in vitro and reduce lethal graft-versus-host disease.TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma model Regulation of immune responses by mTOR.Regulatory T cells, mTOR kinase, and metabolic activity.mTOR, metabolism, and the regulation of T-cell differentiation and function.The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses.The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy

P2860

Q21131224-EA6E7B01-C248-4224-843A-8F868975A415 Q26744649-0E5C8852-6535-44D7-A8FD-7D922F18EAE9 Q26863779-DB5A5B10-51C3-42CF-B987-585887789F87 Q27014722-3259D9D7-A9D4-4730-8D53-A7C4D3951556 Q27319890-C0B1D6FD-04E6-4944-8631-67B285B33D22 Q28297737-D1281AB5-87DE-48E0-AC58-464EFAD9EF06 Q30354732-82D8EE08-B968-4F05-80CF-3E166E1E4914 Q30541884-704C3F3A-CA52-4B1E-92FE-A9D5E7C5B4A0 Q33665207-FA856480-03B1-476D-871E-D0303177802F Q34023880-C8E069BB-0921-4756-A816-9F4A46C6E7FD Q34093292-8717FBDB-2E13-41F8-9503-9495263A89E7 Q34396541-FF27F142-6063-447D-A8AC-D9410A4BB5BD Q34565634-FB86D506-689F-45DA-80A5-8776F82AB36A Q34712316-13B91551-F380-46F1-8AA0-75E32C6334D0 Q34984515-7F1A7A42-7050-4BEC-8A74-720D5A38C00F Q35012411-146FF95E-74C8-4A53-A434-6E4764F082EE Q35087831-8D400F44-526F-4F5E-8B6C-93C162E22A91 Q35621941-A192A12D-0225-40AC-BFCE-43EBF0CF50D9 Q35631301-2E18BE38-2DCB-4783-8C2A-7852DC873AD4 Q35631315-C8A7863A-9097-4CE3-B5D2-FFEF8A69BABF Q35636827-F24641B7-576E-414C-B96D-269DA18B1720 Q36151999-AB0D1424-114E-473E-A975-E0643F501ECA Q36162881-01BBDE72-C41C-4A03-A21F-99ACDBB4D929 Q36473888-6B9A07A9-8142-408A-9231-2B86E29E6B9D Q36639768-9261DAE8-5B98-4224-BAFA-17252338DD86 Q36757048-A8C36841-C98B-44FC-8A20-59FE408A02AF Q37229088-FE084CB0-571B-42D6-A7AA-B1C8A24DA230 Q37246366-E4F5FCB2-2464-479E-B051-ECC9716F78BB Q37307472-135BC147-B768-4FC2-84BB-84A503EBA9BF Q37381720-8A51F698-44D1-4E59-A857-437ADAB37E6E Q37532105-01915C78-5672-42A1-AE45-133F0773F09C Q37661441-CB595EA1-029F-486B-9C33-3679DDFD3F6A Q37672563-33C4B62B-38F7-42B7-980A-B5608DE8FD24 Q37700864-8ABB00C9-89E7-4501-AC00-9A0509FF467E Q37727843-D3869FA2-FEE1-47E7-A724-4DF2415203B4 Q37963950-9ADDB20A-184D-4595-8BDA-417A619B250A Q38023734-3D6DB6E1-897C-45C7-8632-A22DD0FB1A64 Q38034265-9D020ED8-EDC6-45BE-BD6A-562D4D9736FF Q38115702-9B46119F-ABB9-4B5E-8492-054F4529131D Q38190674-4B407D1A-638A-4D09-8DC9-B791E4EFFDCB

P2860

Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production.

http://www.wikidata.org/entity/Q30498613

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Constitutive reductions in mTO ...... ment, and antibody production.

@ast

Constitutive reductions in mTO ...... ment, and antibody production.

@en

type

label

Constitutive reductions in mTO ...... ment, and antibody production.

@ast

Constitutive reductions in mTO ...... ment, and antibody production.

@en

prefLabel

Constitutive reductions in mTO ...... ment, and antibody production.

@ast

Constitutive reductions in mTO ...... ment, and antibody production.

@en

P1433

Q30498613-9E250EF2-37BB-4C6C-BDDA-F9D5C7DB145D

P1476

Q30498613-BC0FA2DE-9766-49E7-832F-A1981BFF11F1

P2093

Q30498613-00D0FFB1-2920-4E8B-AD72-D867857A323A

Q30498613-07B628CC-FEA4-4EE2-AD46-9F962B81C883

Q30498613-0B8A5250-7255-489B-B3FF-322B03F86330

Q30498613-195C63BB-EACE-4BB0-8F04-F3C067894E73

Q30498613-1E9C1774-E3FB-4CE4-A3CD-0F07EE270E9D

Q30498613-242D99A8-C78C-4C77-A756-2B6A0948864D

Q30498613-36214445-A5CD-467F-AD84-172EE67E7EDE

Q30498613-6C0DDFB6-D4BB-48BD-8516-97E048BDE914

Q30498613-6D925A21-295E-4728-930D-15E5284DFF16

Q30498613-8407A00C-A492-4BF2-8C0F-FF24DAFD7AE6

P2860

Q30498613-0CA966FB-E959-4D00-98B5-0951908AC1D4

Q30498613-1172E964-81E8-4B07-967F-A7AB9D6BCE18

Q30498613-18E0A8BA-418A-49FE-B6F7-B3FBCDF1D328

Q30498613-272C35F2-F258-462D-B110-8CB1E0427B84

Q30498613-2C69AE4D-50B3-4454-A960-C21E57C30C71

Q30498613-447ADAAC-10C0-4F44-BC8D-FFE0E4216F82

Q30498613-46CFE854-AC41-492A-A900-3B42155D6C1F

Q30498613-4856E4AA-D9EF-4F08-84DF-4D098A22A810

Q30498613-55A30FAD-BB32-4E17-8E80-AB41D489A0E9

Q30498613-5B6177F5-DF19-4965-8AF5-84A43C052A40

P304

Q30498613-D27EB780-B7F8-49A9-BA73-43A18EEE6FBB

P31

Q30498613-95751711-9C72-43DF-A429-394AAFC3888C

P356

Q30498613-4F28875E-B8E5-4E1B-BC29-89FE0E55937A

P407

Q30498613-8756C8F8-EAD1-4AA8-B2A8-F311643409C3

P433

Q30498613-C045FA75-7B49-49DD-9544-A31AECC765BF

P478

Q30498613-4011D741-74DF-4FA4-9571-FBCE611B7BD1

P577

Q30498613-7FC98345-42CA-4CBA-806B-D19B30DF5DE2

P5875

Q30498613-2140C241-5A37-49E5-A20E-93E62ECBAE69

P698

Q30498613-9722DC41-6A55-480E-ACCB-71608EE51B61

P921

Q30498613-5FA96171-93C6-42FF-A4A7-2BE65DE0C2D2

P932

Q30498613-0B629107-C727-466C-9A61-4AD06B7FEFA6

P356

BLOOD-2010-05-287821

P1433

P1476

Constitutive reductions in mTO ...... ment, and antibody production.

@en

P2093

Beverly A Mock

http://www.w3.org/2001/XMLSchema#string

Carole A Parent

http://www.w3.org/2001/XMLSchema#string

Julie A Readinger

http://www.w3.org/2001/XMLSchema#string

Julie Z Wu

http://www.w3.org/2001/XMLSchema#string

Jyoti Patel

http://www.w3.org/2001/XMLSchema#string

Kaori Sakakibara

http://www.w3.org/2001/XMLSchema#string

Lino Tessarollo

http://www.w3.org/2001/XMLSchema#string

Margaret Pruitt

http://www.w3.org/2001/XMLSchema#string

Mirkka Janka-Junttila

http://www.w3.org/2001/XMLSchema#string

Pamela L Schwartzberg

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development

mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells

Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

TOR controls translation initiation and early G1 progression in yeast

P304

1228-1238

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-05-287821

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47794499

http://www.w3.org/2001/XMLSchema#string

P698

21079150

http://www.w3.org/2001/XMLSchema#string

P921

P932

3056471

http://www.w3.org/2001/XMLSchema#string